These observations might therefore constitute a rationale for assessing complement regulation as a therapeutic target; in a small series of patients, eculizumab, a C5 inhibitor, has recently shown a discrete tolerability in a small series of MS patients, with no severe adverse drug reactions nor disease relapses, supporting further clinical assessment [119]. The gene discussed is C5; the disease is myeloid sarcoma.